Biogen Inc


SKU: BIIB-1 Category:


Biogen has been in the news for a number of controversies, most of which are associated with its Alzheimer’s drug, Aduhelm. The company is looking to shake off the claims that it misled investors on the assumed success of Aduhelm. However, the company did win a priority review from the U.S. FDA for tofersen, its ALS therapy. On the financial front, Biogen executed well in the second quarter and delivered an all-around beat. Along with Eisai, they are granted priority review for lecanemab under the accelerated approval process in the U.S. for early Alzheimer’s disease. Eisai is also advancing the lecanemab Phase III Clarity investigation, with a readout anticipated this fall. With the SKYLARK study results in hand, Biogen is collaborating with Sage to forward one regulatory file for zuranolone in MDD and PPD in the United States, which they anticipate completing in the second part of this year. The company is a key marketing partner for the drug, Byooviz catering to ophthalmology. The management expects to reach the beginning of mid- to late-stage studies for Alzheimer’s, Parkinson’s, and lupus, as well as the regulatory filings for zuranolone for both MDD and PPD in the U.S. in 2022. We maintain our ‘Hold’ rating on Biogen with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!